Eli Lilly and Company
Case brief
What is this about?
The Competition Commission of India approved the acquisition of Novartis Animal Health by Eli Lilly India, finding no appreciable adverse effect on competition based on low market shares and lack of product overlap, despite deferring final market delineation.
What did the court decide?
The combination was approved under Section 31(1) of the Competition Act, 2002.
What the court decided
Fair Competition For Greater Good
COMPETITION COMMISSION OF INDIA
(Combination Registration No. C-2015/07/289)
03.12.2015
Notice given by Eli Lilly and Company pursuant to an inquiry under sub-section (1) of Section 20 of the Competition Act, 2002 (“Act”)
Order under sub-section (1) of Section 31 of the Act
CORAM:
Mr. Ashok Chawla Chairperson
Mr. S. L. Bunker Member
Mr. Sudhir Mital Member
Mr. Augustine Peter Member
Mr. M.S. Sahoo Member Mr. U. C. Nahta Member Mr. G. P. Mittal Member
Issues for consideration
2 issues framed by the court
Whether the acquisition of Novartis Animal Health by Eli Lilly would have an appreciable adverse effect on competition in India.
Whether the relevant product market should be defined at the molecule level or by animal type/therapeutic effect.
Parties & counsel
- applicant
Eli Lilly and Company
- respondent
Novartis
Coram
Ashok Chawla
Case details
As recorded by the court registry
All orders in this case
2 orders share this CNR
- Order 1 — this page
- Order 2
Similar cases
Judgements on the same questions, provisions and authorities, from every court